Advanced in Non-Muscle Invasive Bladder Cancer

Dr. Christos E. Kyriakopoulos

Hematology Oncology | Hematology | Oncology
University Of Wisconsin Medical Foundation Inc
250 Doctors Ct, 
Johnson Creek, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Non-Muscle Invasive Bladder Cancer
University Of Wisconsin Medical Foundation Inc
250 Doctors Ct, 
Johnson Creek, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christos Kyriakopoulos is a Hematologist Oncology specialist and a Hematologist in Johnson Creek, Wisconsin. Dr. Kyriakopoulos is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Kyriakopoulos is currently accepting new patients.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
University Of Wi Hospitals & Clinics Authority
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
250 Doctors Ct, Johnson Creek, WI 53038

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Biological, Drug
Study Drugs: pTVG-HP, pTVG-AR, Pembrolizumab, rhGM-CSF
Study Phase: Phase 2
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drug: IMMU-132
Study Phase: Phase 2
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Gemcitabine, Cisplatin
Study Phase: Phase 2
Pilot Neoadjuvant Trial of Chemohormonal Therapy Followed by Prostatectomy in Patients With High Risk or Oligometastatic Prostate Cancer
Pilot Neoadjuvant Trial of Chemohormonal Therapy Followed by Prostatectomy in Patients With High Risk or Oligometastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug, Radiation
Study Drugs: Docetaxel, Degarelix, Bicalutamide
Study Phase: Early Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

52 Total Publications

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Journal: Investigational new drugs
Published: August 11, 2025
Similar Doctors
Advanced in Non-Muscle Invasive Bladder Cancer
Dr. Anand D. Patel
Oncology | Hematology Oncology | Hematology
Advanced in Non-Muscle Invasive Bladder Cancer
Dr. Anand D. Patel
Oncology | Hematology Oncology | Hematology

Ascension Medical Group-Southeast Wisconsin Inc

19333 W N Ave, 
Brookfield, WI 
 (30.8 miles away)
262-780-4111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anand Patel is an Oncologist and a Hematologist Oncology provider in Brookfield, Wisconsin. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Angiosarcoma, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer. Dr. Patel is currently accepting new patients.

Advanced in Non-Muscle Invasive Bladder Cancer
Dr. Sameer Tolay
Hematology Oncology | Hematology | Oncology
Advanced in Non-Muscle Invasive Bladder Cancer
Dr. Sameer Tolay
Hematology Oncology | Hematology | Oncology

Agnesian Healthcare Inc

480 E Division St, 
Fond Du Lac, WI 
 (51.2 miles away)
920-926-4100
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Sameer Tolay is a Hematologist Oncology specialist and a Hematologist in Fond Du Lac, Wisconsin. Dr. Tolay is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Non-Muscle Invasive Bladder Cancer, and Muscle Invasive Bladder Cancer. Dr. Tolay is currently accepting new patients.

Advanced in Non-Muscle Invasive Bladder Cancer
Dr. Joel H. Lundberg
Hematology Oncology | Hematology | Oncology
Advanced in Non-Muscle Invasive Bladder Cancer
Dr. Joel H. Lundberg
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (37.5 miles away)
414-805-3666
Languages Spoken:
English, German, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Joel Lundberg is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Lundberg is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Hodgkin Lymphoma, Melanoma, Breast Cancer, and Pleuropulmonary Blastoma. Dr. Lundberg is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kyriakopoulos's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile